Katie Salvati
Psychiatric/Mental Health · Lincoln, NENPI 1083005409
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 446 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations.
Across 446 payments — averaging $13.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$934
- Lundbeck LLC$905
- Otsuka America Pharmaceutical, Inc.$677
- Supernus Pharmaceuticals, Inc.$490
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$474
- Teva Pharmaceuticals USA, Inc.$355
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,176100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 109 | $934 |
| Lundbeck LLC | 71 | $905 |
| Otsuka America Pharmaceutical, Inc. | 58 | $677 |
| Supernus Pharmaceuticals, Inc. | 24 | $490 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 31 | $474 |
| Teva Pharmaceuticals USA, Inc. | 24 | $355 |
| Alkermes, Inc. | 19 | $339 |
| Axsome Therapeutics, Inc. | 11 | $210 |
| Johnson & Johnson | 10 | $210 |
| Tris Pharma Inc | 9 | $208 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $136 |
| Neurocrine Biosciences, Inc. | 8 | $124 |
| E.r. Squibb & Sons, L.L.C. | 5 | $117 |
| Biogen | 4 | $90 |
| Acadia Pharmaceuticals Inc | 5 | $90 |
| Sunovion Pharmaceuticals Inc. | 8 | $81 |
| Corium, LLC | 4 | $74 |
| Bausch Health US, LLC | 4 | $72 |
| Neos Therapeutics, LP | 4 | $69 |
| Jazz Pharmaceuticals Inc. | 4 | $64 |
| Noven Therapeutics, LLC | 3 | $61 |
| Vanda Pharmaceuticals Inc. | 3 | $59 |
| Ironshore Pharmaceuticals Inc. | 4 | $57 |
| Itamar Medical Inc | 1 | $49 |
| Idorsia Pharmaceuticals US Inc | 3 | $46 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| Avanir Pharmaceuticals, Inc. | 2 | $30 |
| Almatica Pharma LLC | 2 | $30 |
| Indivior Inc. | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Adlon Therapeutics L.p. | 1 | $15 |
| Merck | 1 | $15 |
| Harmony Biosciences LLC | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $12 |
How this compares
$6,176 in reported general payments places this provider in the 85th percentile of 255 psychiatric/mental health providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 65 | $161,038 |
| Invega SustennaPaliperidone Palmitate | 38 | $138,477 |
| RexultiBrexpiprazole | 95 | $106,683 |
| CaplytaLumateperone Tosylate | 73 | $104,895 |
| IngrezzaValbenazine Tosylate | 18 | $101,592 |
| NuplazidPimavanserin Tartrate | 16 | $81,717 |
| VivitrolNaltrexone Microspheres | 23 | $37,757 |
| TrintellixVortioxetine Hydrobromide | 56 | $20,776 |
| NuedextaDextromethorphan Hbr/Quinidine | 21 | $19,783 |
| Risperdal ConstaRisperidone Microspheres | 16 | $13,047 |
| LinzessLinaclotide | 21 | $11,796 |
| BelsomraSuvorexant | 16 | $10,006 |
| Aripiprazole | 119 | $9,157 |
| Lamotrigine OdtLamotrigine | 35 | $8,379 |
| Duloxetine Hcl | 296 | $8,072 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $355 | $161,03865 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $210 | $151,52454 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $677 | $106,68395 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $474 | $104,89573 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $124 | $101,59218 claims |
| Acadia Pharmaceuticals IncNuplazid | $90 | $81,71716 claims |
| Alkermes, Inc.Vivitrol | $339 | $37,75723 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $136 | $20,77656 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $30 | $19,78321 claims |
| AbbVieLinzess | $934 | $11,79621 claims |
| MerckBelsomra | $15 | $10,00616 claims |
| Axsome Therapeutics, Inc.Sunosi | $210 | $4,83011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 255 psychiatric/mental health providers in Nebraska.
Other psychiatric/mental health in Lincoln
- Helen TrotterLincoln$10K
- Marcia CarlsonLincoln$9K
- Trisha JobmanLincoln$9K
- Cory RabeLincoln$9K
- Kelley HanauLincoln$8K
- Tami OrtonLincoln$8K
- Michelle LemonLincoln$7K
- Serena MacauleyLincoln$7K
- Sabrina HellbuschLincoln$7K
- Rebecca OlanderLincoln$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.